GSK’s Focuses Bioelectronics Quest On Blocking Single-Organ Neural Signals
This article was originally published in The Pink Sheet Daily
Executive Summary
In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.
You may also be interested in...
GSK Ventures Into The Device World Through Bioelectronic Investment
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch
The company launched Amjevita on the same day it announced fourth quarter 2022 earnings and provided 2023 guidance, upping the high-profile nature of the first-to-market US Humira biosimilar.
Gilead Keeps Focus On HIV, Long-Acting Drugs And Growth Through Oncology
Even with top-seller Biktarvy and its preventive therapy, Descovy, protected beyond this decade from generics, Gilead is investing aggressively in long-acting HIV candidates and its oncology pipeline.